Covaxin gets expert panel’s nod for use on 2-18 year olds
Bharat Biotech thanked the DCGI, SEC and CDSCO for expediting the review process. (Representational image) The vaccine Subject Expert Committee (SEC) on Tuesday recommended granting of emergency use authorisation (EUA) for vaccine maker Bharat Biotech’s Covid-19-vaccine, Covaxin, for children in the 2-18 years age group. The SEC has recommended this to the Drugs Controller General … Read more